A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Key claim: E7820 is being evaluated as a treatment for relapsed/refractory myeloid cancers (AML, MDS, CMML) harboring splicing factor gene mutations in an early-phase clinical trial.
Abstract
The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes. Participants will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML).
Why this matters
Splicing factor mutations (SF3B1, SRSF2, U2AF1) are among the most prevalent and disease-defining lesions in CMML and MDS/MPN overlap syndromes, yet no approved therapy targets this mutation class. E7820’s entry into clinical testing across AML, MDS, and CMML introduces a genotype-directed mechanistic axis — splicing modulation — that is mechanistically orthogonal to the HMA, BCL-2, IDH1, FLT3, JAK, CSF-1R, LSD1, ERK, and PLK1 strategies currently dominating these subtype pipelines, and is uniquely positioned to address a shared molecular vulnerability spanning chronic-phase CMML/MDS/MPN and their leukemic transformation.